John G Ullman & Associates Inc. Has $484,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

John G Ullman & Associates Inc. grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,235 shares of the biopharmaceutical company’s stock after buying an additional 257 shares during the period. John G Ullman & Associates Inc.’s holdings in Gilead Sciences were worth $484,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. HHM Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares during the period. YANKCOM Partnership acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $28,000. Decker Retirement Planning Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $29,000. Crews Bank & Trust acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $31,000. Finally, Stephens Consulting LLC grew its holdings in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 260 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 8,500 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $91.96, for a total value of $781,660.00. Following the transaction, the chief financial officer now owns 132,373 shares in the company, valued at approximately $12,173,021.08. This represents a 6.03 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders have sold 293,356 shares of company stock worth $29,166,240. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on GILD. Truist Financial upped their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, November 8th. Maxim Group lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Citigroup began coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They issued a “buy” rating and a $125.00 target price for the company. Robert W. Baird upped their target price on shares of Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Finally, Oppenheimer upped their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $102.08.

Gilead Sciences Stock Up 2.1 %

Shares of GILD stock opened at $114.31 on Friday. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $114.77. The stock has a market cap of $142.46 billion, a price-to-earnings ratio of 308.95, a PEG ratio of 0.71 and a beta of 0.18. The firm’s 50-day moving average is $97.42 and its 200-day moving average is $90.05. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a $0.79 dividend. The ex-dividend date is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.76%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio is 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.